Washington University School of Medicine

Digital Commons@Becker
2020-Current year OA Pubs

Open Access Publications

5-8-2021

Long-term mortality after Histoplasma infection in people with
HIV
Joseph Cherabie
Washington University School of Medicine in St. Louis

Patrick Mazi
Washington University School of Medicine in St. Louis

Adriana M Rauseo
Washington University School of Medicine in St. Louis

Chapelle Ayres
Washington University School of Medicine in St. Louis

Lindsey Larson
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4
Part of the Medicine and Health Sciences Commons

Recommended Citation
Cherabie, Joseph; Mazi, Patrick; Rauseo, Adriana M; Ayres, Chapelle; Larson, Lindsey; Rutjanawech,
Sasinuch; O'Halloran, Jane; Presti, Rachel; Powderly, William G; and Spec, Andrej, "Long-term mortality
after Histoplasma infection in people with HIV." Journal of Fungi (Basel). 7, 5. 369 (2021).
https://digitalcommons.wustl.edu/oa_4/268

This Open Access Publication is brought to you for free and open access by the Open Access Publications at
Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized
administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors
Joseph Cherabie, Patrick Mazi, Adriana M Rauseo, Chapelle Ayres, Lindsey Larson, Sasinuch
Rutjanawech, Jane O'Halloran, Rachel Presti, William G Powderly, and Andrej Spec

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/oa_4/268

Journal of

Fungi
Article

Long-Term Mortality after Histoplasma Infection in People
with HIV
Joseph Cherabie , Patrick Mazi, Adriana M. Rauseo
Jane O’Halloran, Rachel Presti, William G. Powderly

, Chapelle Ayres, Lindsey Larson, Sasinuch Rutjanawech,
and Andrej Spec *

Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine,
St. Louis, MO 63110, USA; jcherabie@wustl.edu (J.C.); pmazi@wustl.edu (P.M.);
a.rauseoacevedo@wustl.edu (A.M.R.); ayreschapelle@wustl.edu (C.A.); lindseylarson@wustl.edu (L.L.);
sasinuchr@wustl.edu (S.R.); janeaohalloran@wustl.edu (J.O.); prestir@wustl.edu (R.P.);
wpowderly@wustl.edu (W.G.P.)
* Correspondence: andrejspec@wustl.edu; Tel.: +1-314-747-1725



Citation: Cherabie, J.; Mazi, P.;
Rauseo, A.M.; Ayres, C.; Larson, L.;
Rutjanawech, S.; O’Halloran, J.; Presti,
R.; Powderly, W.G.; Spec, A.
Long-Term Mortality after

Abstract: Histoplasmosis is a common opportunistic infection in people with HIV (PWH); however,
no study has looked at factors associated with the long-term mortality of histoplasmosis in PWH. We
conducted a single-center retrospective study on the long-term mortality of PWH diagnosed with
histoplasmosis between 2002 and 2017. Patients were categorized into three groups based on length
of survival after diagnosis: early mortality (death < 90 days), late mortality (death ≥ 90 days), and
long-term survivors. Patients diagnosed during or after 2008 were considered part of the modern
antiretroviral therapy (ART) era. Insurance type (private vs. public) was a surrogate indicator of
socioeconomic status. Out of 54 PWH infected with histoplasmosis, overall mortality was 37%; 14.8%
early mortality and 22.2% late mortality. There was no statistically significant difference in survival
based on the availability of modern ART (p = 0.60). Insurance status reached statistical significance
with 38% of survivors having private insurance versus only 8% having private insurance in the late
mortality group (p = 0.05). High mortality persists despite the advent of modern ART, implicating a
contribution from social determinants of health, such as private insurance. Larger studies are needed
to elucidate the role of these factors in the mortality of PWH.
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Histoplasmosis is the most prevalent endemic mycosis in the United States; an estimated 50,778 histoplasmosis-associated hospitalizations occurred between 2001 and 2012
with a trend towards increased incidence [1]. The incidence of histoplasmosis among adults
in the US is highest in the Midwest with 5.1 cases per 100,000 population and common
worldwide among people with HIV/AIDS (PWH) without access to anti-retroviral therapy
(ART) [2].
Histoplasmosis carries a high 90-day mortality of 16%, with mortality increasing
among immunocompromised individuals up to 24% [3]. Previous studies have found that
histoplasmosis, specifically disseminated histoplasmosis, carries a high mortality among
PWH greater than 30%, although many of these studies were performed prior to the era of
modern ART [4,5]. In other opportunistic mycoses, late mortality appears to be significantly
higher than the early mortality initially observed [6].
While multiple studies have assessed factors associated with early mortality from
histoplasmosis among PWH [7–10], to the best of our knowledge no studies have thus
far looked at factors associated with long-term mortality, particularly within the era of
modern ART.
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2. Materials and Methods
This is a retrospective cohort study of patients diagnosed with Histoplasma infection
at Barnes-Jewish Hospital (BJH) in St. Louis, Missouri. BJH is a 1368-bed tertiary care
academic hospital. While located in an urban setting, BJH has a large suburban and rural
catchment area. This study was approved by the Washington University School of Medicine
Human Research Protection Office, with a waiver of informed consent.
The cohort consisted of all individuals diagnosed with Histoplasma capsulatum infection aged 18 or older within BJH from 1 January 2002 until 31 December 2017. Histoplasma
infection required one of the following: (1) positive Histoplasma antigen from urine, serum,
CSF, or other body fluid; (2) microbiologic isolation of H. capsulatum from any source;
(3) coding for International Classification of Diseases (ICD) 9th (115.x) or 10th (B39.X) codes
for Histoplasma infection; or (4) positive Histoplasma antibody. Cases were confirmed independently by two study investigators to ensure cases met criteria for proven or probable
histoplasmosis by MSG/EORTC criteria [11]. Exclusion criteria consisted of the following:
(1) if antigen or antibody testing was positive in the setting of another fungal infection confirmed by culture or histopathology; (2) if an antigen was positive at a low or indeterminate
level and the case was determined to be a false positive by the treating infectious diseases
team at the time and/or by the two study investigators during independent review; (3) if
there was a diagnosis of presumed ocular histoplasmosis syndrome without other evidence
of Histoplasma infection; and (4) if the patient presented with fibrosing mediastinitis. PWH
were then sub-selected if they had a positive 3rd or 4th generation HIV screening test
with positive confirmatory HIV viral load test. Additional information pertaining to each
patient’s HIV infection was obtained from the patients’ charts, including CD4 count and
HIV viral load at time of Histoplasma infection diagnosis, HIV viral load at the time of last
encounter, anti-retroviral experience prior to diagnosis, antiretroviral prescribed at the
time of diagnosis, insurance status, history of other opportunistic infections (OI), history of
substance use, and history of psychiatric illness. Data were collected through automated extraction from the electronic medical record and manual chart review. Other participant data
collected included patient demographics, clinical presentation, organ system involvement
in infection, and mortality.
The primary outcome for our study was all-cause late mortality, defined as deaths
occurring at or after 90 days of histoplasmosis diagnosis. The secondary outcome was
all-cause early mortality, defined as deaths occurring within 90 days of histoplasmosis
diagnosis. Date of death was obtained from the electronic medical record and Social
Security Death Index. The Social Security Death Index includes deaths through 2014 with
deaths after 2014 obtained through the electronic medical record system. If there was
no date of death on record, then it was assumed the patient survived until the last day
the patient interacted with the healthcare system and was right-censored after that date.
Pre-modern ART was defined as a participant having been diagnosed with histoplasmosis
before 2008, and modern ART was a participant having been diagnosed from 2008 onwards,
with 2008 marking the advent of darunavir and integrase inhibitors as standard ART. A
participant was considered virally suppressed if they had a HIV viral load < 50 copies/mL.
Insurance status was categorized into two groups: those with private insurance and
individuals with government insurance (Medicare or Medicaid) or no insurance.
Categorical variables were analyzed using Pearson Chi squared analysis. Continuous
variables were analyzed using Mann–Whitney U non-parametric testing to account for
small numbers and lack of normal distribution. p-values ≤ 0.05 were considered statistically
significant. All statistical analysis was performed using SPSS V25 (IBM, Armonk, NY, USA).
3. Results
Fifty-four individuals were found to have both histoplasmosis as well as HIV infection
within our study period; 68.5% were male and 59.3% were Black. There was no statistically
significant difference between survival groups with respect to age (p = 0.28), gender
(p = 0.91) or race (p = 0.11) (Table 1).
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Table 1. Baseline characteristics and presentation of PWH with histoplasmosis (n = 54) among three
groups (survivors, early mortality, and late mortality) 2002–2017.
Survived
n = 34 (63.0%)
Male
Age (years, median, IQR)
Black
Non-Black
CNS
Pulmonary
Bloodstream
Disseminated disease
Fever
Cough
Night sweats
Dyspnea
Chest pain
Arthralgias
Dysphagia
Weight loss
GI symptoms

Early Mortality
n = 8 (14.8%)

23 (67%)
6 (75%)
43 (32, 51)
41 (36, 49)
Race
16 (47%)
7 (87%)
17 (50%)
1 (13%)
Site of infection
3 (9%)
0 (0%)
24 (71%)
6 (75%)
15 (44%)
3 (38%)
26 (76%)
5 (63%)
Presenting symptoms
26 (76%)
4 (50%)
17 (50%)
4 (50%)
10 (29%)
1 (13%)
13 (38%)
3 (38%)
6 (18%)
0 (0%)
3 (9%)
0 (0%)
5 (15%)
2 (25%)
22 (65%)
5 (63%)
23 (68%)
4 (50%)

Late Mortality
n = 12 (22.2%)
8 (67%)
36 (25, 40)

p-Value
0.91
0.28
0.11

9 (75%)
2 (17%)
0 (0%)
7 (58%)
8 (67%)
11 (92%)

0.39
0.67
0.33
0.29

10 (83%)
5 (42%)
5 (42%)
6 (50%)
3 (25%)
1 (8%)
2 (17%)
5 (42%)
8 (67%)

0.22
0.88
0.38
0.76
0.33
0.69
0.78
0.37
0.64

Overall mortality was 37%. A total of 14.8% (n = 8) of individuals expired within
90 days of histoplasmosis diagnosis with a median length of survival of 13.5 days (IQR
2.5–41), while 22.2% (n = 12) expired on or after 90 days with a median length of survival
of 302 days (IQR 153–710.5). Death occurred within 30 days in 9.3% of individuals (n = 5),
in 31–90 days in 5.5% of individuals (n = 3), in 91–365 days in 13% of individuals (n = 7),
and greater than 365 days in 9.3% of individuals (n = 5). Death occurring within 1 year
had a median survival of 86 days (IQR 6–177) and after 1 year had a median survival of
798 days (IQR 418–993).
Private insurance was a factor more common to the survival group at 38% compared
to 8% of the late mortality group that had private insurance (p = 0.05) (Table 2). There was
no significant difference between survivors and late mortality individuals with respect to
history of substance use (survivors n = 13, 38% survivors vs. late mortality individuals
n = 2, 17%, p = 0.17) or history of psychiatric illness (survivors n = 4, 12%, vs. late mortality
individuals n = 0, 0%, p = 0.21).
Table 2. Baseline HIV-related characteristics of PWH with histoplasmosis (n = 46) among two groups (survivors and late
mortality) 2002–2017.

(cells/mm3 ,

Median CD4 count
median, IQR)
Median HIV viral load at diagnosis (copies/mL, median, IQR)
Median HIV viral load at last observation (copies/mL, median, IQR)
New HIV diagnosis at diagnosis
Median time between HIV and Histoplasma diagnoses (years, median, IQR)
ART-experienced
Modern ART
HIV viral load suppressed at last observation
HIV viral load suppressed at diagnosis
History of previous OIs
Pneumocystis pneumonia
Oral Candidiasis
CMV
Private insurance
History of substance use
History of psychiatric illness

Survived (n = 34)

Late Mortality (n = 12)

p-Value

12 (6, 46)
5.5 (4.4, 6.2)
2.0 (0, 4.5)
18 (53%)
0.2 (0, 13.6)
14 (41%)
12 (35%)
14 (41%)
1 (3%)
17 (50%)
10 (29%)
4 (12%)
2 (6%)
13 (38%)
13 (38%)
4 (12%)

26 (8, 52)
5.2 (3.8, 5.5)
4.1 (2.6, 5.5)
3 (25%)
3.5 (0.1, 5.3)
7 (58%)
4 (33%)
2 (17%)
2 (17%)
9 (75%)
2 (17%)
2 (17%)
2 (17%)
1 (8%)
2 (17%)
0 (0%)

0.52
0.25
0.01
0.10
0.87
0.19
0.90
0.13
0.10
0.13

0.05
0.17
0.21
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3.1. Disease Presentation
Disseminated histoplasmosis was the most common disease presentation within all
groups, occurring in 76% of survivors (n = 26), 63% of individuals with early mortality
(n = 5), and 92% of individuals with late mortality (n = 11), with no statistically significant
difference between the three groups (p = 0.29) (Table 1). Localized pulmonary infection was
common within all three groups (n = 37, 68.5%, p = 0.67), and central nervous system (CNS)
infection was seen in three patients, all of whom survived. As for presenting symptoms,
fever was the most common (74.1%), followed by gastrointestinal symptoms (64.8%) and
cough (48.1%).
3.2. HIV Characteristics
While the median time in years from HIV diagnosis to histoplasmosis diagnosis in
survivors was 3.3 years shorter than among late mortality individuals (0.2 years, IQR
0–13.6 years vs. 3.5 years, IQR 0.1–5.3 years), this difference was not statistically significant
(p = 0.87) (Table 2). Having a new HIV diagnosis at the time of Histoplasma diagnosis was
more common among survivors (n = 18, 53%) compared to late-mortality individuals (n = 3,
25%), but this also did not meet statistical significance (p = 0.10).
HIV viral load at the time of diagnosis with histoplasmosis did not vary significantly
between survivors (5.5 median log copies/mL, IQR 4.4–6.2) and individuals with late
mortality (5.2 median log copies/mL, IQR 3.8–5.5) (p = 0.25). Similarly, there was no
statistically significant difference in viral load suppression (survivors n = 1, 3% vs. late
mortality n = 2, 17%) (p = 0.10) or median CD4 count at the time of Histoplasma infection
diagnosis (median CD4 12 cells/mm3 , IQR 6–46 in survivors vs. median CD4 26 cells/mm3 ,
IQR 8–52 in late mortality individuals, p = 0.52).
Median HIV viral load at last observation was significantly lower in survivors (2 log
copies/mL, IQR 0–4.5) compared to the late mortality individuals (4.1 log copies/mL, IQR
2.6–5.5) (p = 0.01). Survivors (n = 14, 41%) were more than twice as likely to have HIV
viral load suppression at the time of last observation compared to individuals with late
mortality (n = 2, 17%); however, this difference was not statistically significant (p = 0.13).
3.3. ART Experience and Opportunistic Infections
ART experience made no difference with respect to survival (n = 14, 41% of survival
group vs. n = 7, 58% of late mortality group, p = 0.19), nor did being diagnosed with
Histoplasma infection in the era of modern ART (n = 12, 35%, of survival group vs. n = 4,
33% of late mortality group, p = 0.90). Previous opportunistic infections (OIs) occurred
in 50% of the survivor group (n = 17) vs. 75% of the late mortality group (n = 9), with
no significant difference in OI occurrence between the two groups (p = 0.13). The most
common other opportunistic infections overall were Pneumocystis pneumonia, followed by
oral candidiasis and Cytomegalovirus infection. Of all the individuals with late mortality
and OIs, three had no death certificates to indicate cause of death, while three had one or
more OIs other than histoplasmosis active at the time of death.
4. Discussion
This is the first study assessing the long-term mortality of histoplasmosis in a US
population of PWH. Despite the resource-rich environment of US healthcare and most of
our study occurring during the modern era of ART, overall mortality was 37%. This is a
similar mortality rate to the resource-limited environments of French Guiana, Guatemala,
and Brazil—all-cause mortality of 41%, 43.6%, and 30.2%, respectively [11–13]. In the
French Guiana and Guatemalan cohorts, approximately 75% of deaths occurred within
a year of histoplasmosis diagnosis. Our study showed similar findings to these studies,
suggesting that the first 12 months is a critical period for PWH.
The specific cause of each patient’s death is uncertain due to many OIs being listed as
active at the time of death with causes of death being multifactorial. This is often the case
in patients with uncontrolled HIV. Despite this, we identified that HIV viral load at the
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time of diagnosis with histoplasmosis did not vary significantly between survivors and
individuals with late mortality. Similarly, there was no statistically significant difference in
viral load suppression or median CD4 count at the time of Histoplasma infection diagnosis.
Patients presenting in the French Guiana and Guatemala cohorts also had uncontrolled
HIV with median CD4 counts of 31 and 25, respectively.
The advent of integrase inhibitors in 2007–2008 ushered in the modern era of ART.
Modern ART is better tolerated, leads to more rapid viral suppression, and has higher
uptake than historical formulations [14,15]. While the advent of modern ART has had an
effect on the mortality of PWH with other mycoses such as Cryptococcus [6], in our cohort,
being diagnosed with histoplasmosis in the era of modern ART had no effect on survival.
To our knowledge, our study is the first to look at social factors such as private
insurance, mental health, and substance use on the mortality of PWH with histoplasmosis.
A statistically significant improvement in mortality was observed in patients having private
insurance vs. government or no insurance. Health insurance itself is a reflection on
socio-economic status, especially within the US, where individuals with insurance report
significantly greater access and quality of health services compared to individuals who
are uninsured, especially with respect to accessing specialist appointments when private
insurance was compared to Medicaid and uninsured individuals [16]. Negative outcomes
are common among PWH who are uninsured, especially with regard to limited access to
indicated ART regimens, case management, and mental health services [17,18].
Delayed mortality from OIs in PWH is not unique to just histoplasmosis. In PWH
diagnosed with Cryptococcus infection, 66% of deaths occurred after 90 days [6]. Similar to
our study, survivors were more likely to have private insurance. In contrast to our study,
the authors found improved mortality associated with viral suppression at last follow
up. Additionally, they found an improvement in outcomes in the modern ART era and
higher rates of substance use and mental illness in non-survivors [6]. The opposite was
seen in our study, with survivors having higher rates of substance use and a history of
psychiatric illness, and although neither finding was statistically significant, these findings
suggest these factors may not affect mortality in histoplasmosis patients in the same way
as cryptococcosis.
Other OIs in the era of modern ART do not show similar delayed mortality as observed
in histoplasmosis and cryptococcosis. A study of 1264 Taiwanese PWH in the era of
modern ART found 21% of patients had OIs, with the most common being P. jirovecii
(43.4%), followed by Cytomegalovirus (10.4%), tuberculosis (8.1%), and candidiasis (6.9%).
The majority of OI events (91.7%) developed within 90 days and all-cause mortality was
4.4%; 83.9% being OI related etiologies with no significant difference between mortality
rate at 90 days, between 91 and 180 days, and >180 days [19]. These data contrast with our
cohort of PWH with histoplasmosis as their diagnosed OI, where the majority of mortality
occurred more than 90 days after diagnosis.
Small sample size limited our ability to perform multivariate analyses among all three
groups. The early mortality group was too small, with wide confidence intervals in any
comparison, limiting comparisons to the survivor and the late mortality groups. Another
limitation is that our data did not capture whether a patient’s insurance status changed
after their hospitalization. Insurance status is subject to change over time as the result
of many factors; however, due to the size of our study, we considered this a definitive
variable. This study was performed at a single, academic medical center located in the
Midwest, which may limit the generalizability of results to other centers with variable
endemicity of histoplasmosis and to regions where different OIs are more endemic. Lastly,
and possibly most importantly, we were limited by our lack of definitive cause of death
due to the retrospective nature of the study.
In conclusion, the mortality of PWH diagnosed with histoplasmosis remains high,
even in the resource-rich environment of the US medical system, with comparable gross
mortality to similar cohorts in more resource-limited settings [12,13,20]. Despite access
to accurate diagnostics, modern ART, and effective antifungal treatment regimens, our
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US cohort did not trend towards improved mortality as we transitioned in the era of
modern ART, unlike the cohorts from French Guiana, Guatemala, and Brazil. Patients with
government or no insurance were five times more likely to have a late death compared to
patients with private insurance. Though these are complex medical situations with many
confounders, we hypothesize private insurance is a surrogate for a patient’s ability to access
and utilize the US medical system. That PWH in our cohort became immunocompromised
enough to be diagnosed with histoplasmosis and then to experience delayed mortality
beyond the duration of histoplasmosis treatment is likely a failure of the US medical system
to maximize the care this population needs. We recommend additional research including
broadening our cohort to other resource-rich settings to further test our hypothesis and
more fully elucidate the deficiencies in our HIV care model.
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